We changed from ampicillin and gentamicin (AG) to piperacillin-tazobactam (PT) for routine treatment of suspected early-onset sepsis. The rationale for this change included ototoxic and renal toxic effects of gentamicin, resistance to gentamicin in late-onset infections and emergence of ampicillin resistant Escherichia coli. A before and after study was designed before the start of PT administration to monitor whether PT was associated with altered outcomes within the 501 to 1500 g birth weight (Very Low Birth Weight) population. METHOD: Both unmatched and matched comparisons of AG (2007 to 2009) and PT (2010 to 2011) exposed infants are reported. Cohorts were evaluated for initial effectiveness for congenital infections, subsequent morbidities and mortality. RESULT: Data from 714 patients were collected (499 AG and 215 PT in the unmatched and 301 AG and 183 PT in the matched cohorts). No significant differences in demographics or initial Apgar scores were noted in the unmatched or matched comparisons. There were significant differences in many of the outcomes of interest in both the matched and unmatched comparisons including less necrotizing enterocolitis (NEC) and less diaper rash with PT versus AG. The only adverse finding with PT was a small, but statistically significant elevation in alkaline phosphatase. CONCLUSION: Use of PT as the initial empiric antibiotic for very low birth weight infants was not associated with adverse microbiological outcomes. There was no increase in major morbidities. Although outcomes were superior in p1500 g infants treated with PT when compared with AG, the study design does not allow us to conclude that others will see a reduction in NEC or diaper rash if they implement this alternative.
INTRODUCTION
The most commonly used antibiotic combination for therapy of presumed early-onset neonatal sepsis is ampicillin and gentamicin (AG), which is based upon the rationale that the majority of bacterial pathogens which infect newborns are derived from vaginal flora. The most frequent offending gram negative bacteria include Escherichia coli, Haemophilus influenza and Citrobacter sp. The most prevalent gram positive organism is Group B Streptococcus, although this organism has been in decline since the advent of intrapartum prophylaxis with ampicillin. [1] [2] [3] There are many caveats to AG use that are of concern. For example, the dose of ampicillin commonly recommended is insufficient to treat Listeria meningitis, the worst complication of Listeria sepsis. 4, 5 Antenatal exposure to ampicillin increases the risk of necrotizing enterocolitis (NEC) 8 and ampicillin resistant E. coli is prevalent. [1] [2] [3] Prolonged postnatal exposure to empiric antibiotics in neonates has been associated with an increased risk of NEC. [6] [7] [8] Ampicillin also prolongs bleeding times through a direct effect on platelets. 9, 10 An alternative to gentamicin is of interest for several reasons. As much as two percent of the population may have variable 12S ribosomal polymorphisms known to be associated with gentamicin inducible hearing loss. 11 Boles, et al. 12 proposed that neonates about to receive gentamicin should receive genetic screening for these polymorphisms. This would be costly and difficult to accomplish. Second, gentamicin perturbs renal electrolyte excretion and prolonged exposure causes neonatal hypocalcemia. [13] [14] [15] Finally, aminoglycosides relax the ductus arteriosus in a mouse model of ductal closure 16 (but this finding has not been formally investigated in humans).
The only available Cochrane Analysis to address the question of antibiotic superiority for early sepsis concluded that no antibiotic regime could be recommended over another based on currently available data. 17 Some antibiotic choices might not be as good as AG. A large retrospective study found higher mortality with ampicillin and cefotaxime versus AG. 18 In choosing an alternative for our institutions, the following considerations were given: (1) cephalosporins were excluded due to the Clark study, 18 (2) aminoglycosides were excluded due to the Reese study, 16 (3) ampicillin was excluded due to E. coli resistance and the association with NEC, 1-3,6-8 (4) the antibiotic(s) would preferably not require blood draws for levels, (5) the antibiotic(s) would have reasonable coverage of the common pathogens associated with early newborn sepsis, (6) The antibiotic(s) cost would not be prohibitive, (7) the antibiotic(s) would not be commonly reserved or restricted by infectious disease specialists for highly resistant organisms and (8) the antibiotic(s) would ideally already have a history of use (and thus, some reassurance of safety) in the neonatal population.
Piperacillin-tazobactam (PT) is a synthetic penicillin derivative combined with a beta-lactamase inhibitor. It is known to be especially effective for the lung and intestinal infections (which are common sources of entry for fetal infection due to amniotic aspiration or swallowing), and is frequently used in combination with gentamicin in neonates to treat pneumonia. It covers the pathogen families seen in early neonatal sepsis. 19, 20 Levels are not required for dosing, and its spectrum of coverage includes anaerobes, potentially making it favorable to enteric flora balance. Downsides of PT include variable penetration to the cerebrospinal fluid and potential to affect the emergence of drug resistance. We felt the available data supported a change to PT monotherapy as initial broad spectrum coverage for presumed early sepsis in the newborn with the caveat that infants with positive cultures would have immediate conversion to narrow spectrum therapy. This report describes a Phase IV, post implementation, matched and unmatched comparison of the AG historical cohort with the PT implementation cohort.
METHODS

Data collection
We performed a retrospective before and after practice change, cohort study involving 2 NICUs (Wesley Medical Center, Wichita, KS and Tulane Lakeside Hospital, New Orleans, LA, USA). Both institutions received Institutional Review Board approvals for this study. We report both unmatched and matched comparisons of AG exposed (2007 to 2009) and PT exposed infants (2010 to 2011). Inclusion criteria were inborn infants with birth weight of 501 to 1500 g, who had suspected systemic infection and were receiving either AG or PT. During these two periods there were no changes in the indications for initiation of antibiotic coverage. We examined the impact on the Very Low Birth Weight population for two reasons. First, we had existing intervention and outcome data with standardized definitions on all of these infants within our Vermont Oxford Network database and second, these infants stayed well beyond the initial empiric phase and could be monitored for intermediate term impact on colonization or infection as well as toxic effects. Patients with methicillin resistant staphylococcus aureus colonization were to be excluded from this study if they were treated with vancomycin during the empiric phase of therapy (a concern that was exceedingly rare).
Paper and electronic records from the Neodata system were reviewed at Tulane, where as a full electronic data extraction was used at Wesley. Cohorts were evaluated for composite morbidities and mortalities, incidence of sepsis, patent ductus arteriosus treated with indomethacin, ibuprofen or ligation, NEC, ventilator-associated pneumonia (defined as per Vermont Oxford Network) and types of rash (diaper rash and systemic rash -rash outside the diaper area). Other profiles evaluated included neutropenia (o2500 mm À 3 ), thrombocytopenia (o100 000 mm À 3 ), elevated or critically low glucose (o45 or 4125 mg dl
, aspartate aminotransferase 42 Â upper limit normal, alanine aminotransferase 42 Â upper limit normal or alkaline phosphatase 45 Â upper limit normal on Days 1, 2 and 7.
Matching
Comparison groups included both the unmatched before and after cohorts as well as matched cohorts, consisting of one to one or two to computergenerated patient matches (depending on the number of patients available in each cohort) matched by gestation at birth (same week), and, birth weight ( ± 50 g). A SAS (Cary, NC) matching program was used to optimize the total number of infants available for analysis. The time period offered a limited number of patients and the originally planned 2:1 match on the criteria of gestational age (same week) and birth weight (within 50 g) were limiting, so we used a multiple sequence algorithm to match as many total patients altering the number of matches of PT infants to two patients and to one patient until the total available for analysis could not be increased.
Statistics
Statistical methods included Mann À Whitney U, t-test and analysis of variance for nominal and continuous variables. Chi square was used for categorical variables. Descriptive statistics are presented by group for continuous variables. Significance was set at a P-valuep0.0012 using the Bonferroni correction (1/43 variables Â 0.05 P-value for base line significance) to adjust for multiple comparisons.
RESULTS
Population
A total of 714 patients were identified by our search, 499 exposed to AG and 214 exposed to PT. Of these, a maximum match of PT patients to two AG patients could be found for 118 PT patients, and 236 AG patients. 65 patients were added to each group with the subsequent 1:1 match.
Demographics
Unmatched and matched patient cohorts were compared for differences in gestation, birth weight, mode of delivery or gender (Table 1) . No differences were found in either cohort. Race was stable across the study period at both institutions Mortality and common morbidities of prematurity We compared the cohorts for incidence of NEC, severe intraventricular hemorrhage, periventricular leukomalacia, alive and having not failed the newborn hearing screen, length of stay and mortality (Table 1) . We found that there were significant improvement in incidence of NEC with PT treatment compared with AG treatment in both the unmatched and matched analyses.
Miscellaneous outcomes
We assessed systemic rash, diaper rash (data from Wesley patients only), hypoglycemia and hyperglycemia (Table 1) . We found significantly fewer diaper rashes in PT exposed infants within both the unmatched and matched analyses Renal function and electrolytes We analyzed data related to renal function and electrolytes around the time of antibiotic exposure and throughout hospitalization (Supplementary Appendix 1). AG treatment was associated with lower mean calcium values in both the unmatched and matched cohorts and met significance for hypocalcemia in the unmatched analysis, but was just above significance in the matched cohort.
Liver function outcomes
We assessed a panel of traditional markers for liver function for differences between AG and PT treated patients (Supplementary Appendix 2). There were no differences in total or direct bilirubin, aspartate aminotransferase or alanine aminotransferase. However, there was a significant increase in mean alkaline phosphatase associated with PT use (but not incidence of elevated alkaline phosphatase) in both the unmatched and matched analyses.
Cardio-pulmonary interventions and outcomes
We assessed a number of cardio-pulmonary outcomes, including: use of positive end-expiratory pressure devices devices, intubation, ventilator days, ventilator-associated pneumonia, patent ductus arteriosus, patent ductus arteriosus ligation and hypotension. There were no significant differences (Supplementary Appendix 3) .
Empiric antibiotic exposure There was no increase in exposure to the initial antibiotic. The median duration of the initial course of antibiotics was 3 days for Study of piperacillin-tazobactam versus ampicillin/gentamicin E Chong et al both groups with very little variation (Interquartile range was 0) in the unmatched and matched analysis.
Microbiology
We assessed the isolates of all positive cultures throughout the hospital stay and defined them as either early sepsis (day 0 to 2) or late sepsis (day 3 to discharge) (Supplementary Appendix 4) . Organisms causing infection during early sepsis included Group B Streptococcus, E. coli, Citrobacteria and Pseudomonas. The E. coli isolates were all resistant to ampicillin, as was Citrobacteria. One isolate of Pseudomonas was found to be resistant to AG. All of these isolates were sensitive to PT. There were five admission cultures that were considered contaminants, including Bacillus species, Micrococcus species and Corynebacterium species, which were not treated beyond the limited empiric window (an average of 3 days). All early sepsis isolates were from the AG epoch (11) versus none in the PT epoch. There were also more late-onset infections during the AG epoch when compared with the PT epoch (Supplementary Appendix 4) , but neither group reached statistical significance after the Bonferroni correction. There was no change in the type of late-onset organisms or their sensitivities to either AG or PT. We also examined the median time to lateonset sepsis to determine if PT might have altered the timing of sepsis in the unmatched cohort. It was 12 days (with an interquartile range of 14 days) in the AG epoch versus 15.5 days (with and interquartile range of 8 days) in the PT epoch. This was not significantly different (P-value ¼ 0.4384).
DISCUSSION
In this phase IV monitoring study of a practice change, we identified no serious microbiological impact of PT use for suspected neonatal sepsis. A reduction in NEC and diaper rash were each associated with PT. An elevation in alkaline phosphatase was also noted with PT. Further research into this novel finding is required to determine if it is causally related to PT.
In our study periods, all positive blood cultures were reviewed. The organism, interpretation and antibiotic sensitivity were collected. Our first hypothesis, that PT would be sufficient for all congenital infections was correct for all cases of bacteremia. We did not observe a change in late-onset infections or sensitivities between the two treatment eras. Both institutions reserved PT monotherapy for early sepsis, all other use of PT (particularly later life or prolonged use) was in combination with gentamicin or another narrow spectrum gram negative antibiotic as a means to discourage resistance.
There are important limitations to our study. The first is that it is a retrospective, historical controlled observational study, and as such cannot be used to assert causation. Although the timing of our intervention correlated with a reduction in NEC and diaper rash; there may have been other variables in play, which we were unable to capture in this detailed study (although we are not sure what they might be-for example, there was no known change in antepartum antibiotic use or concurrent change in care across both neonatal intensive care units).
CONCLUSION
We describe a successful two center experience with PT monotherapy versus AG as empiric therapy for suspected congenital sepsis in infants o1500 g. Reductions in NEC and diaper rash were noted in the PT treated patients. 
